Thomson Medical Group has launched its Johor Bay integrated project that will have a gross development value of RM18 billion.

 

The development, sitting on a 26-acre site within the Johor-Singapore Special Economic Zone, will include healthcare, luxury residential and hospitality, commercial, and lifestyle elements.

 

The development is also sited just 1.2km from the upcoming RTS station at Bukit Chagar and minutes from the Causeway and regional ferry terminals.

 

Thomson Medical Group, controlled by former Remisier King Peter Lim, calls this project " the most expansive private healthcare and real estate ventures on prime land in Southeast Asia to-date."

 

With the Thomson Hospital Iskandariah as one of the anchor developments, the project aims to ride on the momentum of Johor&rsquo s attractive balance of high standards of living and manageable living costs the imminent completion of the RTS and the increasing momentum behind the JSSEZ.

 

&ldquo The time is right: economic tailwinds, infrastructure momentum, and demographic shifts are converging," says Kiat Lim, executive vice chairman of Thomson Medical Group.

 

" We have built a vision for a mega project that will shape the skyline and the future of the JSSEZ bay area for years to come," he adds.

 

The first phase of the project includes the Thomson Hospital Iskandariah and a 47-storey " ultra-luxury" residential tower.

 

YAB Dato&rsquo Onn Hafiz bin Ghazi, Menteri Besar of Johor, says this project is a timely and strategic development that supports the state&rsquo s long-term goals.

 

" Not only will the Thomson Hospital Iskandariah project help strengthen Johor&rsquo s position as a premier healthcare hub in Southeast Asia, but the wider Johor Bay project will add to our overall economic growth agenda under the JS-SEZ."

 

HEALTHCARE provider Thomson Medical Group has named Gleneagles Hospital&rsquo s chief executive officer (CEO) Melvin Heng as its executive director and group CEO, with effect from Dec 1.

 

Heng will be succeeding Wong Chiang Yin, who resigned in late August to pursue personal interests after more than two years* into the role. His last day was on Sep 30.

 

According to Thomson Medical&rsquo s filing on Friday (Oct 7) morning, Heng &ndash who has been chief executive at rival IHH Healthcare&rsquo s Gleneagles since the start of 2021 &ndash will continue to serve at his current role until Oct 31 before joining Thomson Medical. 

 

Prior to his appointment as Gleneagles&rsquo CEO, Heng joined the IHH brand in September 2017 as assistant vice-president of operations before taking on the role of chief operating officer in July 2019.

 

Heng was previously a medical adviser at Singapore&rsquo s Ministry of Health from 2016 to 2018. In 2018, he co-founded digital healthcare startup Mesh Bio, where he remains an alternate director. He was listed as a co-founder of Global Medical Concierge from 2013 to 2017.

 

In the earlier years of his career, Heng worked as a medical doctor at the UK&rsquo s National Health Service as well as Singapore&rsquo s Tan Tock Seng Hospital.

 

Heng has an MBBS (Bachelor of Medicine and Bachelor of Surgery) from the University of London, St Georges Hospital a graduate diploma in occupational medicine from the University of Singapore and a Masters of Business Administration from the Frankfurt School of Finance & Management.

 

He is currently listed as a director of a private limited company in Singapore, Astrid Park Capital.